The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process to a global audience. The global approach can help customers move to batches for clinical trials in ...

RANCHO CORDOVA, Calif., March 12, 2026 (GLOBE NEWSWIRE)-- SK pharmteco today announced the successful CGMP qualification of its manufacturing facility in Corbeil-Essonnes, France. This ...

Kite Pharma's viral vector plant in Southern California has been cleared for liftoff, and, with that, the Gilead Sciences company is touting its position as the only cell therapy player able to make ...

Gene therapies can correct diseases at their genetic core, but their success hinges on viral vector manufacturing. As gene therapy technology becomes more advanced, producing viral vectors becomes ...

DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...

Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...

MALVERN, Pa.--(BUSINESS WIRE)--Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing ...

SYDNEY, March 18, 2026 (GLOBE NEWSWIRE)-- Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), ...

- New, $110 million facility will more than double existing production capacity - Supports large-scale commercial manufacturing of viral and gene therapy products BURLINGTON, Mass., April 21, 2020 ...

DUBLIN, July 13, 2023 /PRNewswire/ -- The "Viral Vector and Plasmid DNA Manufacturing Market - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. The global viral ...

Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. The purpose of the ...

Oxford, UK - 18 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into a licensing and option agreement with Viral Vector ...